(Glycosylphosphatidylinositol-Based) Protein Chips and Biosensors for Biopharmaceutical Process Analytics

New Challenges for Biopharmaceutical Process Development.PDF

The U.S. Food and Drug Administration (FDA), through the Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER), has long identified that the development of biopharmaceutical products is becoming increasingly challenging, and is inefficient and costly. The agency has also commented that superior product-development sciences are needed to address the c...

Biopharmaceutical Process Evaluated for Viral Clearance

© 2009 Microbac Laboratories, Inc. Page 1 of 7 The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential viral contaminants. Experience and knowledge in selecting the most relevant target viruses, appropriate purification steps, and viral clearing agents are critical in the design and implementation of a cos...

Peptide and Protein Design for Biopharmaceutical Applications

Non-antibody protein-based biosensors

Biosensors that depend on a physical or chemical measurement can be adversely affected by non-specific interactions. For example, a biosensor designed to measure specifically the levels of a rare analyte can give false positive results if there is even a small amount of interaction with a highly abundant but irrelevant molecule. To overcome this limitation, the biosensor community has frequentl...

Nanobiosensors and fluorescence based biosensors: An overview

A biosensor can sense biological elements after interaction with the recognition element. The signal produced due to interaction of the analyte with its biochemical element is transduced by a transducer and detected by appropriate modes. The miniaturization of these biosensors at the nano level using nanostructures as a platform for sensing the analyte or its detection is called a nanobiosensor...